Details of the Drug

General Information of Drug (ID: DMDRQZU)

Drug Name
Ethanol
Synonyms
Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA
Indication
Disease Entry ICD 11 Status REF
Chronic pain MG30 Approved [1]
Cystic tumor of the pancreas N.A. Approved [2]
Cystitis GC00 Approved [1]
Therapeutic Class
Analgesics
Affected Organisms
Humans and other mammals
ATC Code
D08AX08: Ethanol
D08AX: Other antiseptics and disinfectants
D08A: ANTISEPTICS AND DISINFECTANTS
D08: ANTISEPTICS AND DISINFECTANTS
D: DERMATOLOGICALS
V03AB16: Ethanol
V03AB: Antidotes
V03A: ALL OTHER THERAPEUTIC PRODUCTS
V03: ALL OTHER THERAPEUTIC PRODUCTS
V: VARIOUS
V03AZ01: Ethanol
V03AZ: Nerve depressants
V03A: ALL OTHER THERAPEUTIC PRODUCTS
V03: ALL OTHER THERAPEUTIC PRODUCTS
V: VARIOUS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 46.07
Logarithm of the Partition Coefficient (xlogp) -0.1
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Absorption
The drug is rapidly absorbed []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
2.5% of drug is excreted from urine in the unchanged form [3]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2170.63257 micromolar/kg/day [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Alcohol poisoning Not Available STAT3 OTAAGKYZ [6]
Alcohol poisoning Not Available FOS OTJBUVWS [6]
Alcohol poisoning Not Available OGFR OTROS6RJ [6]
Alcoholic pancreatitis rs12688220 MORC4 OTJBEHNE [7]
Alcoholic pancreatitis rs10273639 PRSS1 OTA425AX [7]
Blood insulin abnormal Not Available EIF4E OTDAWNLA [6]
Blood insulin abnormal Not Available EIF4EBP1 OTHBQVD5 [6]
Blood insulin abnormal Not Available RPS6A OTIG8G1R [6]
Blood insulin abnormal Not Available INS OTZ85PDU [6]
Bone lesion Not Available SHBG OTPWU5IW [6]
Hyperparathyroidism Not Available PTH1R OTQF5ZAK [6]
Liver injury Not Available IRS2 OT46MJBE [6]
Liver injury Not Available GAPDH OTBPMIMW [6]
Liver injury Not Available PIK3C2A OTFBU4GD [6]
Liver injury Not Available IRS1 OTNO82CU [6]
Mitochondrial toxicity Not Available SLC25A11 OT7EVFBK [6]
Neurotoxicity Not Available GABAB1 OT8KS945 [6]
Pancreatic disorder Not Available REG3A OT0BVQRB [6]
Pancreatitis acute Not Available MPO OTOOXLIN [6]
Pancreatitis chronic Not Available DRD2 OTBLXKEG [6]
Stevens-Johnson syndrome HLA-B*38:01 HLA-B OTNXFWY2 [8]
⏷ Show the Full List of 21 ADR Information of This Drug
Chemical Identifiers
Formula
C2H6O
IUPAC Name
ethanol
Canonical SMILES
CCO
InChI
InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3
InChIKey
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
702
ChEBI ID
CHEBI:16236
CAS Number
64-17-5
UNII
3K9958V90M
DrugBank ID
DB00898
TTD ID
D00AMQ
VARIDT ID
DR00377
INTEDE ID
DR0655
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Antagonist [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Aldo-keto reductase 1A1 (AKR1A1) DED2FW3 AK1A1_HUMAN Substrate [13]
Alcohol dehydrogenase class-I alpha (ADH1A) DEE5M8O ADH1A_HUMAN Substrate [14]
Alcohol dehydrogenase class-V (ADH6) DE017IC ADH6_HUMAN Substrate [13]
Gastric alcohol dehydrogenase (ADH7) DEZMAHX ADH7_HUMAN Substrate [13]
Alcohol dehydrogenase class-III (ADH5) DEIOH6A ADHX_HUMAN Substrate [13]
Alcohol dehydrogenase class-I beta (ADH1B) DEEN9RD ADH1B_HUMAN Substrate [14]
Alcohol dehydrogenase class-II (ADH4) DEOCWU3 ADH4_HUMAN Substrate [15]
Alcohol dehydrogenase class-I gamma (ADH1C) DEM1HNL ADH1G_HUMAN Substrate [14]
Alcohol dehydrogenase (ADH) DEG8NJD A0A2I1XAT4_NEISI Substrate [16]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
10 kDa heat shock protein, mitochondrial (HSPE1) OT7JSZLB CH10_HUMAN Gene/Protein Processing [17]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Gene/Protein Processing [18]
2'-5'-oligoadenylate synthase 3 (OAS3) OT6E5FYS OAS3_HUMAN Drug Response [19]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Drug Response [20]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Gene/Protein Processing [21]
5-hydroxymethyl-dUMP N-hydrolase (DNPH1) OTEZVTI1 DNPH1_HUMAN Gene/Protein Processing [22]
5-hydroxytryptamine receptor 1D (HTR1D) OTLS74AF 5HT1D_HUMAN Gene/Protein Processing [23]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) OT25JBA3 F263_HUMAN Gene/Protein Processing [24]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) OTQYEXL2 F264_HUMAN Gene/Protein Processing [23]
6-phosphogluconolactonase (PGLS) OTO6C0IQ 6PGL_HUMAN Gene/Protein Processing [25]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ethanol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [26]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Ethanol and Oliceridine. Acute pain [MG31] [27]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Ethanol and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [28]
Metronidazole DMTIVEN Major Decreased metabolism of Ethanol caused by Metronidazole mediated inhibition of non-CYP450 enzyme. Amoebiasis [1A36] [29]
Cefamandole DMNEXZF Moderate Decreased metabolism of Ethanol caused by Cefamandole mediated inhibition of non-CYP450 enzyme. Anaerobic bacterial infection [1A00-1A09] [30]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [31]
Chlormezanone DMTWUXR Moderate Additive CNS depression effects by the combination of Ethanol and Chlormezanone. Anxiety disorder [6B00-6B0Z] [28]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Ethanol and Desipramine. Attention deficit hyperactivity disorder [6A05] [32]
Cefotetan DM07TX3 Moderate Decreased metabolism of Ethanol caused by Cefotetan mediated inhibition of non-CYP450 enzyme. Bacterial infection [1A00-1C4Z] [30]
Tindamax DM3OWT4 Moderate Decreased metabolism of Ethanol caused by Tindamax mediated inhibition of non-CYP450 enzyme. Bacterial infection [1A00-1C4Z] [29]
Cefoperazone DM53PV8 Moderate Decreased metabolism of Ethanol caused by Cefoperazone mediated inhibition of non-CYP450 enzyme. Bacterial infection [1A00-1C4Z] [30]
Cariprazine DMJYDVK Moderate Additive CNS depression effects by the combination of Ethanol and Cariprazine. Bipolar disorder [6A60] [28]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Ethanol and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [33]
Diphenoxylate DMO5SZX Moderate Additive CNS depression effects by the combination of Ethanol and Diphenoxylate. Bowel habit change [ME05] [28]
Nifurtimox DMSQLZJ Major Decreased metabolism of Ethanol caused by Nifurtimox mediated inhibition of non-CYP450 enzyme. Chagas disease [1F53] [34]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Ethanol and Dihydrocodeine. Chronic pain [MG30] [35]
Levetiracetam DMTGDN8 Moderate Additive CNS depression effects by the combination of Ethanol and Levetiracetam. Chronic pain [MG30] [28]
Levomilnacipran DMV26S8 Moderate Additive CNS depression effects by the combination of Ethanol and Levomilnacipran. Chronic pain [MG30] [28]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Ethanol and Anisindione. Coagulation defect [3B10] [36]
Azelastine DMXTMBJ Moderate Additive CNS depression effects by the combination of Ethanol and Azelastine. Conjunctiva disorder [9A60] [28]
Levonorgestrel DM1DP7T Minor Decreased metabolism of Ethanol caused by Levonorgestrel. Contraceptive management [QA21] [37]
Norgestimate DMYP4XC Minor Decreased metabolism of Ethanol caused by Norgestimate. Contraceptive management [QA21] [38]
Methoxyflurane DML0RAE Moderate Additive CNS depression effects by the combination of Ethanol and Methoxyflurane. Corneal disease [9A76-9A78] [28]
Ketamine DMT5HA4 Moderate Additive CNS depression effects by the combination of Ethanol and Ketamine. Corneal disease [9A76-9A78] [26]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Ethanol and Remifentanil. Corneal disease [9A76-9A78] [27]
Chlophedianol DMXGJEI Moderate Additive CNS depression effects by the combination of Ethanol and Chlophedianol. Cough [MD12] [28]
Sertraline DM0FB1J Moderate Additive CNS depression effects by the combination of Ethanol and Sertraline. Depression [6A70-6A7Z] [28]
Cyclobenzaprine DM1YBRM Moderate Additive CNS depression effects by the combination of Ethanol and Cyclobenzaprine. Depression [6A70-6A7Z] [28]
Vilazodone DM4LECQ Moderate Additive CNS depression effects by the combination of Ethanol and Vilazodone. Depression [6A70-6A7Z] [28]
Nefazodone DM4ZS8M Moderate Additive CNS depression effects by the combination of Ethanol and Nefazodone. Depression [6A70-6A7Z] [28]
Selegiline DM6034S Moderate Additive CNS depression effects by the combination of Ethanol and Selegiline. Depression [6A70-6A7Z] [28]
Vortioxetine DM6F1PU Moderate Additive CNS depression effects by the combination of Ethanol and Vortioxetine. Depression [6A70-6A7Z] [28]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Ethanol and Isocarboxazid. Depression [6A70-6A7Z] [28]
Escitalopram DMFK9HG Moderate Additive CNS depression effects by the combination of Ethanol and Escitalopram. Depression [6A70-6A7Z] [28]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Ethanol and Desvenlafaxine. Depression [6A70-6A7Z] [28]
OPC-34712 DMHG57U Moderate Additive CNS depression effects by the combination of Ethanol and OPC-34712. Depression [6A70-6A7Z] [28]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Ethanol and Doxepin. Depression [6A70-6A7Z] [32]
Maprotiline DMPWB7T Moderate Additive CNS depression effects by the combination of Ethanol and Maprotiline. Depression [6A70-6A7Z] [28]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Ethanol and Esketamine. Depression [6A70-6A7Z] [28]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Ethanol and Mepenzolate. Digestive system disease [DE2Z] [39]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Ethanol and Oxybutynine. Discovery agent [N.A.] [39]
Heroin diacetylmorphine DMDBWHY Moderate Additive CNS depression effects by the combination of Ethanol and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [35]
Tetrabenazine DMYWQ0O Moderate Additive CNS depression effects by the combination of Ethanol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [28]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Ethanol and Deutetrabenazine. Dystonic disorder [8A02] [28]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Ethanol and Ingrezza. Dystonic disorder [8A02] [28]
Fomepizole DM6VOWQ Major Decreased metabolism of Ethanol caused by Fomepizole mediated inhibition of non-CYP450 enzyme. Eexposure to noxious substances harmful effect [NE61] [40]
Oestradiol valerate and dienogest DMZK0FQ Minor Decreased metabolism of Ethanol caused by Oestradiol valerate and dienogest. Endometriosis [GA10] [38]
Zonisamide DM0DTF7 Moderate Additive CNS depression effects by the combination of Ethanol and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [28]
Felbamate DM1V5ZS Moderate Additive CNS depression effects by the combination of Ethanol and Felbamate. Epilepsy/seizure [8A61-8A6Z] [28]
Methsuximide DM6L5VO Moderate Additive CNS depression effects by the combination of Ethanol and Methsuximide. Epilepsy/seizure [8A61-8A6Z] [28]
Gabapentin DM6T924 Moderate Additive CNS depression effects by the combination of Ethanol and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [28]
Cenobamate DM8KLU9 Moderate Additive CNS depression effects by the combination of Ethanol and Cenobamate. Epilepsy/seizure [8A61-8A6Z] [28]
Tiagabine DMKSQG0 Moderate Additive CNS depression effects by the combination of Ethanol and Tiagabine. Epilepsy/seizure [8A61-8A6Z] [28]
Fosphenytoin DMOX3LB Moderate Additive CNS depression effects by the combination of Ethanol and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [26]
Brivaracetam DMSEPK8 Moderate Additive CNS depression effects by the combination of Ethanol and Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [28]
Clonazepam DMTO13J Moderate Additive CNS depression effects by the combination of Ethanol and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [41]
Lacosamide DMVM6QR Moderate Additive CNS depression effects by the combination of Ethanol and Lacosamide. Epilepsy/seizure [8A61-8A6Z] [28]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Ethanol and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [42]
Vigabatrin DMYT0OG Moderate Additive CNS depression effects by the combination of Ethanol and Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [28]
Eslicarbazepine DMZREFQ Moderate Additive CNS depression effects by the combination of Ethanol and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [28]
Cannabidiol DM0659E Moderate Additive CNS depression effects by the combination of Ethanol and Cannabidiol. Epileptic encephalopathy [8A62] [28]
Diphenhydramine DMKQTBA Moderate Additive CNS depression effects by the combination of Ethanol and Diphenhydramine. Episodic vestibular syndrome [AB31] [39]
Dantrolene DM1D8XY Moderate Additive CNS depression effects by the combination of Ethanol and Dantrolene. Fever [MG26] [28]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Ethanol and Tolterodine. Functional bladder disorder [GC50] [39]
Ketoconazole DMPZI3Q Minor Decreased metabolism of Ethanol caused by Ketoconazole mediated inhibition of non-CYP450 enzyme. Fungal infection [1F29-1F2F] [43]
Abacavir DMMN36E Minor Decreased metabolism of Ethanol caused by Abacavir mediated inhibition of non-CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Ethanol and Mipomersen. Hyper-lipoproteinaemia [5C80] [45]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Ethanol and Teriflunomide. Hyper-lipoproteinaemia [5C80] [46]
Belladonna DM2RBWK Moderate Additive CNS depression effects by the combination of Ethanol and Belladonna. Infectious gastroenteritis/colitis [1A40] [39]
Suvorexant DM0E6S3 Moderate Additive CNS depression effects by the combination of Ethanol and Suvorexant. Insomnia [7A00-7A0Z] [28]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Ethanol and Amobarbital. Insomnia [7A00-7A0Z] [42]
Ramelteon DM7IW9J Moderate Additive CNS depression effects by the combination of Ethanol and Ramelteon. Insomnia [7A00-7A0Z] [28]
Zaleplon DMGFWSM Moderate Additive CNS depression effects by the combination of Ethanol and Zaleplon. Insomnia [7A00-7A0Z] [28]
Tasimelteon DMLOQ1V Moderate Additive CNS depression effects by the combination of Ethanol and Tasimelteon. Insomnia [7A00-7A0Z] [28]
Paraldehyde DMOC1BX Moderate Additive CNS depression effects by the combination of Ethanol and Paraldehyde. Insomnia [7A00-7A0Z] [28]
ITI-007 DMUQ1DO Moderate Additive CNS depression effects by the combination of Ethanol and ITI-007. Insomnia [7A00-7A0Z] [28]
Quazepam DMY4D87 Moderate Additive CNS depression effects by the combination of Ethanol and Quazepam. Insomnia [7A00-7A0Z] [41]
Estazolam DMZGXUM Moderate Additive CNS depression effects by the combination of Ethanol and Estazolam. Insomnia [7A00-7A0Z] [41]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [47]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Idelalisib. Mature B-cell leukaemia [2A82] [48]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Ethanol caused by Ethinyl estradiol. Menopausal disorder [GA30] [38]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Ethanol and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [28]
Flibanserin DM70DTN Major Additive CNS depression effects by the combination of Ethanol and Flibanserin. Mood disorder [6A60-6E23] [49]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Ethanol and Thalidomide. Multiple myeloma [2A83] [28]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Ethanol and Phenindamine. Nasopharyngitis [CA00] [28]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Ethanol and Cyclizine. Nausea/vomiting [MD90] [39]
Metoclopramide DMFA5MY Moderate Additive CNS depression effects by the combination of Ethanol and Metoclopramide. Nausea/vomiting [MD90] [28]
E-2007 DMJDYNQ Moderate Additive CNS depression effects by the combination of Ethanol and E-2007. Neuropathy [8C0Z] [28]
Phendimetrazine DM6TS1N Moderate Additive CNS depression effects by the combination of Ethanol and Phendimetrazine. Obesity [5B80-5B81] [50]
Amfepramone DM9YSNQ Moderate Additive CNS depression effects by the combination of Ethanol and Amfepramone. Obesity [5B80-5B81] [50]
Sibutramine DMFJTDI Moderate Additive CNS depression effects by the combination of Ethanol and Sibutramine. Obesity [5B80-5B81] [50]
Dexfenfluramine DMJ7YDS Moderate Additive CNS depression effects by the combination of Ethanol and Dexfenfluramine. Obesity [5B80-5B81] [50]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Ethanol and Levomethadyl Acetate. Opioid use disorder [6C43] [49]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Ethanol and Lofexidine. Opioid use disorder [6C43] [28]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Ethanol and Apraclonidine. Optic nerve disorder [9C40] [51]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Ethanol and Oxymorphone. Pain [MG30-MG3Z] [27]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Ethanol and Dezocine. Pain [MG30-MG3Z] [27]
Flavoxate DMKV4NL Moderate Additive CNS depression effects by the combination of Ethanol and Flavoxate. Pain [MG30-MG3Z] [28]
Methamphetamine DMPM4SK Moderate Additive CNS depression effects by the combination of Ethanol and Methamphetamine. Pain [MG30-MG3Z] [52]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Ethanol and Buprenorphine. Pain [MG30-MG3Z] [53]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Ethanol and Hydrocodone. Pain [MG30-MG3Z] [54]
Ziconotide DMSLJP4 Moderate Additive CNS depression effects by the combination of Ethanol and Ziconotide. Pain [MG30-MG3Z] [28]
Safinamide DM0YWJC Moderate Additive CNS depression effects by the combination of Ethanol and Safinamide. Parkinsonism [8A00] [28]
Pergolide DM14MAE Moderate Additive CNS depression effects by the combination of Ethanol and Pergolide. Parkinsonism [8A00] [28]
Opicapone DM1BKA6 Moderate Additive CNS depression effects by the combination of Ethanol and Opicapone. Parkinsonism [8A00] [28]
Rasagiline DM3WKQ4 Moderate Additive CNS depression effects by the combination of Ethanol and Rasagiline. Parkinsonism [8A00] [28]
Levodopa DMN3E57 Moderate Additive CNS depression effects by the combination of Ethanol and Levodopa. Parkinsonism [8A00] [28]
Bromocriptine DMVE3TK Moderate Additive CNS depression effects by the combination of Ethanol and Bromocriptine. Parkinsonism [8A00] [28]
Orphenadrine DMW542E Moderate Additive CNS depression effects by the combination of Ethanol and Orphenadrine. Parkinsonism [8A00] [28]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Ethanol and Methylscopolamine. Peptic ulcer [DA61] [39]
Neupro DMHEAB1 Moderate Additive CNS depression effects by the combination of Ethanol and Neupro. Restless legs syndrome [7A80] [28]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Ethanol and Leflunomide. Rheumatoid arthritis [FA20] [46]
Aripiprazole DM3NUMH Moderate Additive CNS depression effects by the combination of Ethanol and Aripiprazole. Schizophrenia [6A20] [28]
Iloperidone DM6AUFY Moderate Additive CNS depression effects by the combination of Ethanol and Iloperidone. Schizophrenia [6A20] [28]
Paliperidone DM7NPJS Moderate Additive CNS depression effects by the combination of Ethanol and Paliperidone. Schizophrenia [6A20] [28]
Molindone DMAH70G Moderate Additive CNS depression effects by the combination of Ethanol and Molindone. Schizophrenia [6A20] [28]
Thiothixene DMDINC4 Moderate Additive CNS depression effects by the combination of Ethanol and Thiothixene. Schizophrenia [6A20] [28]
Asenapine DMSQZE2 Moderate Additive CNS depression effects by the combination of Ethanol and Asenapine. Schizophrenia [6A20] [28]
Pimozide DMW83TP Moderate Additive CNS depression effects by the combination of Ethanol and Pimozide. Schizophrenia [6A20] [28]
Avanafil DM75CXN Moderate Additive hypotensive effects by the combination of Ethanol and Avanafil. Sexual dysfunction [HA00-HA01] [55]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Ethanol and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [55]
Chlorpheniramine DM5URA2 Moderate Additive CNS depression effects by the combination of Ethanol and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [28]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Ethanol and Acrivastine. Vasomotor/allergic rhinitis [CA08] [28]
⏷ Show the Full List of 123 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2299).
2 Ethanol FDA Label
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet. 2012 Dec;44(12):1349-54. doi: 10.1038/ng.2466. Epub 2012 Nov 11.
8 A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008 Feb;18(2):99-107. doi: 10.1097/FPC.0b013e3282f3ef9c.
9 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
10 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
11 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
12 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
13 Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
14 Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25.
15 Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
16 Functional profiles of coronal and dentin caries in children. J Oral Microbiol. 2018 Jul 16;10(1):1495976.
17 Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
18 cAMP/PKA/EGR1 signaling mediates the molecular mechanism of ethanol-induced inhibition of placental 11beta-HSD2 expression. Toxicol Appl Pharmacol. 2018 Aug 1;352:77-86.
19 The potential effects of HECTD4 variants on fasting glucose and triglyceride levels in relation to prevalence of type 2 diabetes based on alcohol intake. Arch Toxicol. 2022 Sep;96(9):2487-2499. doi: 10.1007/s00204-022-03325-y. Epub 2022 Jun 17.
20 Substance dependence low-density whole genome association study in two distinct American populations. Hum Genet. 2008 Jun;123(5):495-506. doi: 10.1007/s00439-008-0501-0. Epub 2008 Apr 26.
21 Alcohol depletes coenzyme-Q(10) associated with increased TNF-alpha secretion to induce cytotoxicity in HepG2 cells. Toxicology. 2012 Dec 8;302(1):34-9.
22 The use of genomics technology to investigate gene expression changes in cultured human liver cells. Toxicol In Vitro. 2001 Aug-Oct;15(4-5):399-405. doi: 10.1016/s0887-2333(01)00043-1.
23 Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
24 Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
25 Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
26 Cerner Multum, Inc. "Australian Product Information.".
27 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
28 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
29 Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985): 292-3. [PMID: 4027157]
30 Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982): 621-2. [PMID: 6214982]
31 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
32 Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
33 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
34 Product Information. Lampit (nifurtimox). Bayer Pharmaceutical Inc, West Haven, CT.
35 Edwards C, Gard PR, Handley SL, Hunter M, Whittington RM "Distalgesic and ethanol-impaired function." Lancet 2 (1982): 384. [PMID: 6124782]
36 Breckenridge A "Clinical implications of enzyme induction." Basic Life Sci 6 (1975): 273-301. [PMID: 239673]
37 Hobbes J, Boutagy J, Shenfield GM "Interactions between ethanol and oral contraceptive steroids." Clin Pharmacol Ther 38 (1985): 371-80. [PMID: 4042520]
38 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
39 Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
40 Product Information. Antizol (fomepizole). Jazz Pharmaceuticals, Palo Alto, CA.
41 Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
42 Gupta RC, Kofoed J "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J 94 (1966): 863-5. [PMID: 5929537]
43 Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
44 Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
45 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
46 Canadian Pharmacists Association.
47 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
48 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
49 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
50 Product Information. Suprenza (phentermine). Akrimax Pharmaceuticals, Cranford, NJ.
51 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
52 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
53 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
54 Product Information. Zohydro ER (HYDROcodone). Zogenix, Inc, San Diego, CA.
55 Cerner Multum, Inc. "UK Summary of Product Characteristics.".